For many common antihypertensive agents, including alpha blockers, beta blockers, and calcium channel blockers, there are limited data to guide the choice of antihypertensive therapy in the setting of HFpEF.172 Nevertheless, RAAS inhibition with ACE inhibitor, ARB (especially mineralocorticoid receptor antagonists), and possibly ARNI would represent the preferred choice. A shared decision-making discussion with the patient influenced by physician judgment should drive the ultimate choice of antihypertensive agents. 9.6. Sleep-Disordered Breathing: Recommendations (Moved from Section 7.3.1.4, Treatment of Sleep Disorders in the 2013 HF guideline.) Recommendations for Treatment of Sleep Disorders COR LOE Recommendations Comment/Rationale IIa C-LD In patients with NYHA class II IV HF and suspicion of sleep-disordered breathing or excessive daytime sleepiness, a formal sleep assessment is NEW: Recommendation reflects clinical necessity to distinguish obstructive versus central sleep apnea. See Online Data Supplement G. Sleep disorders are common in patients with HF. A study of adults with chronic HF treated with evidence-based therapies found that 61% had either central or obstructive sleep apnea.202 It is clinically important to distinguish obstructive sleep apnea from central sleep apnea, given the different responses to treatment. Adaptive servo-ventilation for central sleep apnea is associated with harm.203 Continuous positive airway pressure (CPAP) for obstructive sleep apnea improves sleep quality, reduces the apnea-hypopnea index, and improves nocturnal oxygenation.200,201 IIb B-R In patients with cardiovascular disease and obstructive sleep apnea, CPAP may be reasonable to improve sleep quality and daytime NEW: New data demonstrate the limited scope of benefit expected from CPAP for obstructive sleep apnea. 